Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP Pyruvate MRI for predicting ASI response in CRPC
NCT02911467Phase 1Terminated
- Sponsor
- Rahul Aggarwal
- Start
- Nov 2016
- Primary completion
- Jul 2020
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Pyruvic acid in prostate cancer (PCa), sponsored by Rahul Aggarwal. Primary endpoint: Mean difference in baseline intra-tumoral peak lac/pyr ratio on HP C-13 MRI at 6 months. Started Nov 2016; status: terminated.
02
Drugs
Pyruvic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02911467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911467.